Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,089 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Cheng Z, Su B, Su X, Song W, Guo Y, Liao L, Chen X, Li J, Tan X, Xu F, Pang S, Wang K, Ye J, Wang Y, Chen L, Sun J, Ji L. Gao L, et al. Diabetes Obes Metab. 2023 Mar;25(3):785-795. doi: 10.1111/dom.14926. Epub 2022 Dec 12. Diabetes Obes Metab. 2023. PMID: 36433709 Clinical Trial.
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, Cai C, Deng H, Feng L, Song B, Ma Q, Qian L. Ji L, et al. Among authors: gao l. EClinicalMedicine. 2022 Oct 7;54:101691. doi: 10.1016/j.eclinm.2022.101691. eCollection 2022 Dec. EClinicalMedicine. 2022. PMID: 36247927 Free PMC article.
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
Ji L, Lu J, Gao L, Yan X, Li J, Cheng Z, Zhang L, Tian J, Li P, Bai J, Xie D, Zhao J, Ding J, Yu Q, Wang T. Ji L, et al. Among authors: gao l. Diabetes Obes Metab. 2023 Dec;25(12):3788-3797. doi: 10.1111/dom.15274. Epub 2023 Sep 19. Diabetes Obes Metab. 2023. PMID: 37724698 Clinical Trial.
Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).
Gao L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Wu Y, Garg SK, Ji L. Gao L, et al. Among authors: gao y. J Diabetes. 2020 Sep;12(9):668-676. doi: 10.1111/1753-0407.13046. Epub 2020 May 29. J Diabetes. 2020. PMID: 32329194
17,089 results
You have reached the last available page of results. Please see the User Guide for more information.